PAGENAX

This brand name is authorized in Nigeria.

Active ingredients

The drug PAGENAX contains one active pharmaceutical ingredient (API):

1	Brolucizumab UNII XSZ53G39H5 - BROLUCIZUMAB
	Brolucizumab is a humanised monoclonal single chain Fv (scFv) antibody fragment with a molecular weight of ~26 kDa. Brolucizumab binds with high affinity to VEGF-A isoforms, thereby preventing binding of VEGF-A to its receptors VEGFR-1 and VEGFR-2. By inhibiting VEGF-A binding, brolucizumab suppresses endothelial cell proliferation, thereby reducing pathological neovascularisation and decreasing vascular permeability.
	Read more about Brolucizumab

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A6-100100	Solution for injection (Inravitreal)	PAGENAX 120MG/ML SOLUTION FOR INJECTION INJ_SOL 120 mg/mL 1 x 0.23mL	Single use. 0.23 mL in 1 mL Ph. Eur. Type I colourless glass vial with grey rubber stoppper and an aluminum seal with violet flip-off cap +1 1⁄2" 18G filter needle in a soft blister (Box of 1's).	02/04/2023

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
S01LA06		S Sensory organs → S01 Ophthalmologicals → S01L Ocular vascular disorder agents → S01LA Antineovascularisation agents
Discover more medicines within S01LA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A6-100100